Alnylam Files Answer and Counterclaim Related to Tekmira Lawsuit

Alnylam Pharmaceuticals, Inc. ALNY has filed an answer and counterclaim to an amended complaint filed by Tekmira Pharmaceuticals Corporation TKMR in the Business Litigation Session of the Massachusetts Superior Court. Alnylam has also disclosed a research agreement and a related supplemental agreement with Tekmira and other third parties. “Alnylam continues to believe that the complaint filed by Tekmira is without merit or foundation, and the company intends to fully defend itself in this matter,” said Barry Greene, President and Chief Operating Officer of Alnylam. “Our focus remains on the advancement of RNAi therapeutics to patients and execution on our clinical programs.”